Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:01 2024-07-11 pm EDT 5-day change 1st Jan Change
224.9 USD +0.48% Intraday chart for Becton, Dickinson and Company -1.24% -7.75%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Health Care Up in Anticipation of Deal Activity -- Health Care Roundup DJ
FDA Reports Supply Interruptions for Becton Dickinson BD BACTEC Culture Media Bottles DJ
US FDA flags shortage of Becton Dickinson's blood test tubes RE
Becton, Dickinson Says it Exceeded 2023 Emissions Reduction Targets MT
Citigroup Adjusts Price Target on Becton, Dickinson to $255 From $260 MT
Goldman Sachs Adjusts Price Target on Becton, Dickinson to $262 From $274 MT
Evercore ISI Adjusts Price Target on Becton, Dickinson to $285 From $290, Maintains Outperform Rating MT
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool CI
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 CI
Evercore ISI Raises Becton, Dickinson and Company's Price Target to $290 From $282 MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash DJ
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
DBS Bank Adjusts Price Target on Becton, Dickinson to $285 From $300 MT
Transcript : Becton, Dickinson and Company Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Exclusive-Biden to put tariffs on China medical supplies - sources RE
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating MT
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021. CI
Evercore ISI Raises Becton, Dickinson and Company Price Target to $282 From $280 MT
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Sector Update: Health Care MT
Chart Becton, Dickinson and Company
More charts
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
223.9 USD
Average target price
277.8 USD
Spread / Average Target
+24.09%
Consensus
  1. Stock Market
  2. Equities
  3. BDX Stock
  4. News Becton, Dickinson and Company
  5. Goldman Sachs Adjusts Price Target on Becton, Dickinson to $262 From $274